Introduction
Guillain-Barré syndrome (GBS) is an acquired acute neuropathy and covers the spectrum of acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher syndrome, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN) and acute pandysautonomia. GBS can affect both peripheral and cranial nerves and generally has a rapid progressive course with ascending paresis of the limbs and reduction or absence of reflexes. It is assumed that activation of T cells results in antibody production against protein antigens on peripheral nerves causing their damage. Viral and bacterial agents (especially campylobacter jejuni), immunisation, surgical treatments, drugs and neoplastic diseases are considered in the aetiology (1, 2) . Neurological involvement is observed in 5-25% of patients with lymphoma being either the first presentation of the disease or emerging during its course (3, 4) .
In this short report, we present a patient with primary extranodal non-Hodgkin's lymphoma (NHL) of the colon who developed GBS during the disease course.
Case
A 66-year-old male patient presented with abdominal pain and loss of weight. He was examined due to similar complaints in another centre in September 2007. Computed tomography (CT) of the abdomen revealed thickening of the cecal wall and lymphadenomegaly in the peripheral mesenteries. Colonoscopy had shown a giant ulcerated mass lesion located in the distal part of the terminal ileum and cecum. The patient underwent a right hemicolectomy ( Figure 1A ). Histological examination of the mass showed a tumour containing high-grade atypical cells ( Figure  1B ) which were CD20 (+), LCA (+), CD3 (-) and cytokeratin (-). The patient was diagnosed with ileocecal large B-cell lymphoma and treated with 5 cycles of adjuvant chemotherapy including cyclophosphamide 750 mg/m 2 day 1, epirubicin 50 mg/m 2 day 1, vincristine 1.4 mg/m 2 (max 2 mg) day 1, prednisone 100 mg/m 2 day 1-5 (CEOP) every three weeks. After the 5 th cycle of therapy, the patient refused treatment and had not been followed up further.
The patient was seen in our outpatient clinic in July 2008. Positron Emission Tomography/Computed Tomography (PET/CT) scanning revealed increased fluorodeoxyglucose (FDG) uptake in the area of the terminal ileum and adjacent conglomerated enlarged lymph nodes. The patient was diagnosed with a regional relapse and a new combination chemotherapy including cyclophosphamide 750 mg/m 2 day 1, doxorubicin 50 mg/m 2 day 1, vincristine 1.4 mg/m 2 (max 2 mg) day 1, prednisone 100 mg/m 2 day 1-5, rituximab 375 mg/m 2 day 0 (R-CHOP), every tree weeks, was initiated.
Seven weeks after starting chemotherapy, the patient complained of severe fatigue, weakness in both limbs and difficulty in walking. He was normothermic (36.8°C), slightly tachycardic (heart rate: 100/min), mildly hypertensive (blood pressure: 170/100 mmHg) and had a slight orthostatic hypotension.
The neurological examination revealed unaffected cranial nerves, symmetrical severe paresis of the lower limbs (muscle strength 3/5 according to the medical research council [MRC] grading system in the proximal muscles, and 2/5 in the distal muscles) and symmetrical slight paresis of upper distal muscles (muscle strength +4/5). Deep tendon reflexes were completely absent, there was no Babinski reflex or any other pyramidal sign. Sense of touch was reduced in both lower limbs up to the level of the knee. Sense of vibration was completely lost at the distal parts of the lower limbs. Cerebrospinal fluid (CSF) examination showed slightly elevated protein level (59 mg/dl) and no cells. Anti-GQ1a, anti-GQ1b and anti-GM antibodies were negative. In addition, protein electrophoresis and serum IgG were within normal ranges. Viral serology of serum and CSF was levels also negative. Magnetic resonance imaging (MRI) of the cranium and spinal cord was normal. Nerve conduction studies and needle electromyography (EMG) showed an acquired demyelinating polyneuropathy (PNP) which was accompanied by axonal loss. A decrease in compound muscle action potentials, prolongation of distal motor latencies and a reduction in motor conduction velocities were observed. Sensory action potentials were completely absent, median, ulnar and tibial F waves could not be obtained and needle electromyography showed signs of early denervation (Table 1a and 1b).
The patient was diagnosed with GBS, and intravenous immunoglobulin (IVIG) was administered at doses of .4 g/kg/ day for 5 consecutive days. On the first day of treatment, the patient developed respiratory insufficiency due to respiratory muscle weakness and, oxygen saturation dropped to 80%. He was transferred to the intensive care unit (ICU) and he recovered on day 3. The treatment was completed in the ICU. A slight improvement of motor functions in the lower limbs was observed on examination but there was no change in deep sensation. Four weeks after initiation of treatment, muscle strength in distal limbs improved slightly, and sensation of vibration was weakly detected. Unfortunately, 2 months later, the patient died due to progression and complications of lymphoma. 
Discussion
The pathophysiological relationship between GBS and cancer is not established yet, but a mechanism of paraneoplastic origin is blamed (5). Antibodies developing against tumour cell antigens are supposed to cause damage of the peripheral nerves due to molecular mimicry. However, this theory is losing ground if there are no antibodies found in the CSF and sera of patients, which is the case in approximately 30% (4, 6) . Neoplastic diseases also suppress or modulate the immune system, and thereby can lead to GBS, considering the occurrence of GBS after surgery, infections, transplantation or HIV infections all causing immune suppression to various degrees (4).
To date, approximately 25 cases of GBS occurring together with lymphoma in adults have been published. Approximately 65% of these cases are NHL, whereas 35% are Hodgkin's lymphoma. In Table 2 , we summarized the characteristics of patients with GBS and lymphoma published more recently, between 2000 and 2012 (2 [index case], 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19) . To our knowledge, an association between GBS and primary extranodal intestinal lymphoma is not reported yet.
The underlying cause of neurological involvement during lymphoma is mostly neurotoxicity due to chemotherapeutic agents or direct invasion of peripheral nerves and nerve roots by tumour cells. The side effect of vincristine constitutes the major cause for peripheral neuropathy (9, 20, 21) , although cytosine arabinoside and rituximab are also accused (10, 11, 14, 15) . The clinical spectrum can vary from mild paresthesia to serious quadriplegia.
In our case, there was an acute onset of symmetrical sensorimotor PNP starting in the distal parts and spreading proximally over days. Arterial hypertension, tachycardia and orthostatic hypotension were also observed and indicated involvement of the autonomic nervous system. Symptoms of the patient started approximately 7 weeks after the initial dose of chemotherapy. It could be assumed that the neurotoxic effect of vincristine was the cause. The cumulative dose of vincristine in our case was 4 mg, however, vincristine neuropathy occurs rarely at doses of 1.4 mg/m 2 , unless there is an underlying disease, such as diabetic PNP, Charcot-Marie-Tooth disease or HIV infection (20, 21) . In these cases, severe neuropathies can be observed at even much lower doses. Additionally, vincristine is known to cause a predominantly axonal PNP (22) , whereas in our case demyelination was definitely prominent, which further supported the diagnosis of GBS. In our patient, tests for HIV were negative, he did not suffer from diabetes mellitus and the family history for hereditary neuropathies was negative. In addition, the electro-diagnostic findings, the slight elevation of protein in the CSF and the moderate response to IVIG were all supporting the diagnosis of GBS. Furthermore, there were no cells in the CSF, gadoliniumenhanced cranial and spinal MRI scans were unremarkable and the cancer was in remission when symptoms of GBS first developed. In conclusion, there was no reason to assume that peripheral nerves were infiltrated by tumour cells.
One other major aspect in the differential diagnosis of GBS is chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP may also accompany lymphoproliferative diseases, such as lymphomas or plasmocytomas. Some authors suggest that CIDP is the chronic form of GBS. It is generally assumed that the disease continues to progress for about 8 weeks (23) . Although electrodiagnostic features and CSF findings resemble GBS, the very slow progression of symptoms, its chronic relapsing course, the finding of monoclonal gammopathy of undetermined significance (MGUS) in 40-50% of patients, and a good response to treatment with corticosteroids are making the differential diagnosis easier (24) . In our case, the acute onset, rapid progression and recovery after 4 weeks was prominent. Additionally, there was no gammopathy either, thus, CDIP was excluded.
In conclusion, we think it is important to recognise the clinical picture as early as possible to establish the differential diagnosis and to initiate treatment rapidly. It must be kept in mind that this syndrome may have a fatal outcome or at least may lead to permanent disability. 
